A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies

Table 1 PGA Confirmatory Factor Analysis

Study	CFI^a (constrained paths)	CFI^a (unconstrained paths)		Difference between path coefficients (constrained vs unconstrained), %
Study	CFI^a (constrained paths)	CFI^a (unconstrained paths)		Erythema	Induration	Scaling
OPT Pivotal 1	0.995	0.996	Baseline	−18.1	16.7	4.2
OPT Pivotal 1	0.995	0.996	Week 16	0.5	1.9	−1.6
OPT Pivotal 2	0.983	0.995	Baseline	−9.5	18.7^*	−5.0
OPT Pivotal 2	0.983	0.995	Week 16	−5.5^*	5.0	−1.8
OPT Compare	0.988	0.997	Baseline	−16.8^*	16.6^*	0.6
OPT Compare	0.988	0.997	Week 12	−3.2	5.5	−3.9
OPT Retreatment	0.981	0.994	Baseline	−34.3^*	38.9^*	0.8
OPT Retreatment	0.981	0.994	Week 24	−6.0	2.8^*	0.9

ISSN: 1471-5945